Jardiance Indications/Uses

Type 2 diabetes mellitus: Glycaemic control: JARDIANCE is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Reduction of risk of cardiovascular death: JARDIANCE is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Heart failure: JARDIANCE is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Chronic kidney disease: JARDIANCE is indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (CKD Stages 2 and 3A with urine ACR ≥30 mg/g, or CKD Stages 3B, 4 and 5 irrespective of urine ACR).